Prognostic factors for cure following treatment of onychomycosis

被引:57
作者
Sigurgeirsson, B. [1 ]
机构
[1] Univ Iceland, Dept Dermatol, Reykjavik, Iceland
关键词
onychomycosis; prognostic factors; therapy; ORAL ANTIFUNGAL AGENTS; DERMATOPHYTE ONYCHOMYCOSIS; CONTINUOUS TERBINAFINE; TOENAIL ONYCHOMYCOSIS; DOUBLE-BLIND; PREVALENCE; NAIL; INTERMITTENT; EPIDEMIOLOGY; ITRACONAZOLE;
D O I
10.1111/j.1468-3083.2009.03487.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective To examine if host baseline factors and week 24 mycology results are associated with mycological and clinical cure in patients with onychomycosis treated with oral terbinafine. Design Open pilot study to determine prognostic factors in the treatment of onychomycosis. Setting Outpatient dermatology clinic. Patients A total of 199 patients from the Icelandic arm of a trial comparing continuous terbinafine with intermittent terbinafine in onychomycosis were recruited for additional observation. Main outcome measures Mycological, clinical and complete cure of the target toenail 72 weeks after treatment was initiated. Results Patients with matrix involvement or slow nail growth were less likely to reach mycological, clinical and complete cure. Lateral involvement affected complete and mycological cure rates negatively. Patients with a dermatophytoma were less likely to reach mycological cure. Patients with a history of prior infection, men and older patients were less likely to reach clinical cure. Positive culture at 24 weeks affected mycological and clinical cure at 72 weeks negatively. Limitations Only patients treated with terbinafine were considered. Conclusions Several host-related factors at baseline and positive culture at 24 weeks had negative effects on cure of onychomycosis 72 weeks after treatment was initiated. This finding merits a large study on prognostic outcome factors in onychomycosis.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 19 条
[1]  
Baran R, 1996, ACTA DERM-VENEREOL, V76, P82
[2]   Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis [J].
Baran, R .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 145 :15-19
[3]   Office practice-based confirmation of onychomycosis - A US nationwide prospective survey [J].
Elewski, BE ;
Leyden, J ;
Rinaldi, MG ;
Atillasoy, E .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (18) :2133-2138
[4]   Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis [J].
Evans, EGV ;
Sigurgeirsson, B .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7190) :1031-1035
[5]   Modulation of linear nail growth to treat diseases of the nail [J].
Geyer, AS ;
Onumah, N ;
Uyttendaele, H ;
Scher, RK .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (02) :229-234
[6]   Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients [J].
Gupta, AK ;
Jain, HC ;
Lynde, CY ;
MacDonald, P ;
Cooper, EA ;
Summerbell, RC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :244-248
[7]  
Gupta AK, 1999, EUR J DERMATOL, V9, P633
[8]  
HEIKKILA H, 1995, BRIT J DERMATOL, V133, P699
[9]   Epidemiology of onychomycosis in special-risk populations [J].
Levy, LA .
JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 1997, 87 (12) :546-550
[10]  
Niewerth M, 1999, DRUGS, V58, P283, DOI 10.2165/00003495-199958020-00005